

**Form 51-102F3**  
**Material Change Report**

**Item 1 Name and Address of Company**

Biocure Technology Inc. (the "Company")  
950-1130 West Pender Street  
Vancouver, B.C. V6E 4A4

**Item 2 Date of Material Change**

January 20, 2020

**Item 3 News Release**

A news release was disseminated on January 20, 2020 through the facilities of Newswire.

**Item 4 Summary of Material Change**

The Company's wholly owned subsidiary, Biocurepharm Corporation ("BPK") has closed a non-brokered private placement to raise gross proceeds of \$662,892.

**Item 5 Full Description of Material Change**

BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea ("BPK"), BPK has issued 53,567 ordinary shares at an approximate price of \$12.375 CAD per share for gross proceeds of \$662,892. All dollar values were based on the exchange rate of CAD0.001125 = 1 KRW as published by the Bank of Canada on January 17, 2020.

Following the completion of the placement, CURE holds a 94.47% interest in BPK on an undiluted basis and will hold a 92.05% interest in BPK on a fully diluted basis.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8 Executive Officer**

Sang Mok Lee is knowledgeable about the material change and the Report and may be contacted (604) 609-7146.

**Item 9**

**Date of Report**

January 21, 2020